Asked by: John Glen (Conservative - Salisbury)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, what discussions NICE has had with the EU institutions on the proposed Joint Action 3 on health technology appraisals.
Answered by George Freeman
In October 2015, the Department nominated the National Institute for Health and Care Excellence (NICE) as a partner organisation in the planned third Joint Action on Health Technology Assessment (HTA).
NICE has advised that it has had a number of discussions with European Commission officials, as well as other partner organisations, about NICE’s participation in this planned Joint Action.
The Department is responsible for the policy framework for the assessment of health technologies and officials remain in close contact with NICE regarding the European Union collaboration in HTA, including the proposals for the production of joint products as part of the third Joint Action.
Asked by: John Glen (Conservative - Salisbury)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, what representations he has received from NICE on the potential merits of a European relative effectiveness assessment to inform health technology appraisals.
Answered by George Freeman
In October 2015, the Department nominated the National Institute for Health and Care Excellence (NICE) as a partner organisation in the planned third Joint Action on Health Technology Assessment (HTA).
NICE has advised that it has had a number of discussions with European Commission officials, as well as other partner organisations, about NICE’s participation in this planned Joint Action.
The Department is responsible for the policy framework for the assessment of health technologies and officials remain in close contact with NICE regarding the European Union collaboration in HTA, including the proposals for the production of joint products as part of the third Joint Action.
Asked by: John Glen (Conservative - Salisbury)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, what discussions he has had with NICE on its policy on a European relative effectiveness assessment for new drugs.
Answered by George Freeman
In October 2015, the Department nominated the National Institute for Health and Care Excellence (NICE) as a partner organisation in the planned third Joint Action on Health Technology Assessment (HTA).
NICE has advised that it has had a number of discussions with European Commission officials, as well as other partner organisations, about NICE’s participation in this planned Joint Action.
The Department is responsible for the policy framework for the assessment of health technologies and officials remain in close contact with NICE regarding the European Union collaboration in HTA, including the proposals for the production of joint products as part of the third Joint Action.
Asked by: John Glen (Conservative - Salisbury)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, how many hospital admissions due to liver disease there were in (a) England and (b) each parliamentary constituency in the last year for which figures are available.
Answered by Jane Ellison
The information requested is in the attached table.
Asked by: John Glen (Conservative - Salisbury)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, what the total cost of treating liver disease was in (a) England and (b) each parliamentary constituency in the last year for which figures are available.
Answered by Jane Ellison
Information on the total cost of treating liver disease in England and in each parliamentary constituency is not available centrally.
Such information as is available is from reference costs, which are the average unit cost to National Health Service hospital trusts of providing defined services to patients in a given financial year. Reference costs for acute care are collected by Healthcare Resource Group (HRG), which are standard groupings of similar treatments that use similar resources. HRGs are organised by chapters and sub-chapters, representing different body systems, and HRG sub-chapter GC describes hepatobiliary and pancreatic system disorders. The total costs in the following table, calculated from the national average unit costs and activity submitted in reference costs, will therefore include the costs to NHS hospitals of treating liver and liver related diseases, but also the costs of other related disorders.
Estimated total costs (£ millions) to NHS hospitals of treating hepatobiliary and pancreatic system disorders, 2014-15
Liver failure disorders | £17.7 million |
Malignant, hepatobiliary or pancreatic disorders | £54.3 million |
Non-malignant, hepatobiliary or pancreatic disorders | £328.1 million |
Total costs | £400.0 million |
Source: reference costs, Department of Health
Notes:
Liver Failure Disorders with Multiple Interventions
Liver Failure Disorders with Single Intervention
Liver Failure Disorders without Interventions, with CC (Complication and Comorbidity) Score 5+
Liver Failure Disorders without Interventions, with CC Score 0-4
Malignant, Hepatobiliary or Pancreatic Disorders, with Multiple Interventions
Malignant, Hepatobiliary or Pancreatic Disorders, with Single Intervention, with CC Score 5+
Malignant, Hepatobiliary or Pancreatic Disorders, with Single Intervention, with CC Score 2-4
Malignant, Hepatobiliary or Pancreatic Disorders, with Single Intervention, with CC Score 0-1
Malignant, Hepatobiliary or Pancreatic Disorders, without Interventions, with CC Score 6+
Malignant, Hepatobiliary or Pancreatic Disorders, without Interventions, with CC Score 3-5
Malignant, Hepatobiliary or Pancreatic Disorders, without Interventions, with CC Score 1-2
Malignant, Hepatobiliary or Pancreatic Disorders, without Interventions, with CC Score 0
Non-Malignant, Hepatobiliary or Pancreatic Disorders, with Multiple Interventions, with CC Score 9+
Non-Malignant, Hepatobiliary or Pancreatic Disorders, with Multiple Interventions, with CC Score 4-8
Non-Malignant, Hepatobiliary or Pancreatic Disorders, with Multiple Interventions, with CC Score 0-3
Non-Malignant, Hepatobiliary or Pancreatic Disorders, with Single Intervention, with CC Score 9+
Non-Malignant, Hepatobiliary or Pancreatic Disorders, with Single Intervention, with CC Score 4-8
Non-Malignant, Hepatobiliary or Pancreatic Disorders, with Single Intervention, with CC Score 0-3
Non-Malignant, Hepatobiliary or Pancreatic Disorders, without Interventions, with CC Score 8+
Non-Malignant, Hepatobiliary or Pancreatic Disorders, without Interventions, with CC Score 5-7
Non-Malignant, Hepatobiliary or Pancreatic Disorders, without Interventions, with CC Score 2-4
Non-Malignant, Hepatobiliary or Pancreatic Disorders, without Interventions, with CC Score 0-1
Asked by: John Glen (Conservative - Salisbury)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, if NHS England will issue a consultation on a new Prioritisation Framework for making decisions on investment in specialised services and highly specialised services.
Answered by George Freeman
In its response to the public consultation "Investing in Specialised Services" in June 2015, NHS England described the work planned to further develop a prioritisation framework for specialised services. This document stated that NHS England will ensure there is proper stakeholder engagement, potentially including a short formal consultation.
NHS England is currently testing a potential method for prioritisation for use in the 2016/17 business planning round, and will decide if a formal consultation is appropriate as part of this process.
Asked by: John Glen (Conservative - Salisbury)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, what plans NHS England has to involve NICE in the specialised commissioning policy development process.
Answered by George Freeman
NHS England is in discussions with the National Institute for Health and Care Excellence in relation to two areas of potential support to its clinical commissioning policy development process for directly commissioned specialised services from 2016/17.
The first is the delivery of rapid evidence reviews (systematic reviews of the available evidence of clinical effectiveness for particular treatments and indications). The second is the production of commissioning support documents for licenced drugs which NHS England commissions directly.
Asked by: John Glen (Conservative - Salisbury)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, if NHS England will publish a list of the commissioning policies scheduled to be developed in (a) 2015-16, (b) 2016-17 and (c) 2017-18.
Answered by George Freeman
There are no plans for NHS England to publish the list of clinical policies in development.
Asked by: John Glen (Conservative - Salisbury)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, if NHS England will publish the (a) agendas and (b) minutes of all future meetings of the (i) Clinical Advisory Group and (ii) Specialised Commissioning Committee within a reasonable period after each such meeting takes place.
Answered by George Freeman
The specialised services commissioning committee provides regular updates of its business to NHS England's public board, of which a summary is published online.
NHS England is considering how to further improve transparency, while not inhibiting the free and frank exchange of views.